Fabtech Technologies Limited · NSE:FABTECH
Fabtech Technologies — Q2 & H1 FY27 Earnings Presentation
35 slides from Fabtech Technologies's earnings presentation, Oct 30, 2026
Slide 1: Cover letter to stock exchanges
Date: October 30, 2026 To, National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Listing Department Bandra Kurla Complex, Floor 25, P J Towers, Bandra (East), Mumbai – 400051 Dalal Street, Mumbai – 400001 Maharashtra, India. Maharashtra, India. Symbol: FABTECH Scrip Code
Slide 2: Fabtech Technologies Limited Investor Presentation Q2 & H1FY27
FABTECH TECHNOLOGIES LIMITED Engineering the capability behind the future of healthcare Integrated | Global | Asset Light | Engineering led Pharma | Biotech | Healthcare | Advanced Manufacturing Design & Build Enabling Science Engineering life In vesto r Pr esen tation - Q2 & H1FY27
Slide 3: Disclaimer
Disclaimer This document has been prepared for information purposes only and is not an offer or invitation or recommendation to buy or sell any securities of Fabtech Technologies Ltd, nor shall part, or all, of this document form the basis of, or be relied on in connection with, any contract or inve
Slide 4: About Us
About Us Every vaccine, IV solution, inhaler and Start to Finish Design & Build turnkey biotech product is made inside a certified, 06 01 provider that designs, engineers, builds and 62+ Countries sterile facility – our area of expertise. validates those facilities — for pharma, biotech and healthca
Slide 5: Performance Highlights
Performance Highlights Investor Presentation - Q2 & H1FY27 4
Slide 6: Business Highlights
Business Highlights Strong EBITDA Growth Revenue Recovery Expected in H2 New Market Entry EBITDA (incl. other income) more than Revenue and profitability are expected to The Company enters a CIS country with a doubled QoQ, up 110% to ₹155.7 mn in Q2 improve as planned project milestones new turnkey
Slide 7: Operational Update
Operational Update Business resilience & momentum Order book & growth visibility H1 navigated geopolitical uncertainty and freight Healthy order book: Rs. 900 crore (2.2x FY26 Revenue) volatility across GCC markets. Additional prospective orders from Africa and Saudi Arabia: Rs. 800-850 crore. The e
Slide 8: Consolidated Income Statement – Q2/H1 FY27
Consolidated Income Statement – Q2/H1 FY27 Particulars (INR Mn) Q2FY27 Q1FY27 Q2FY26 QoQ% H1FY27 H1FY26 Revenue From Operations 920.9 749.8 1,214.8 22.8 1,670.7 1,894.9 Other Income 54.5 31.7 28.0 72.2 86.2 37.4 Total Income 975.4 781.5 1,242.8 24.8 1,756.9 1,932.3 Total Expenditure 819.7 707.4 910.
Slide 9: Strategic Priorities
Strategic Priorities Accelerate project delivery and business Advance capabilities in cell and gene 01 development across Africa and the UAE 02 therapy facilities, other high-technology while managing Saudi project timelines. projects and data-centre infrastructure. Exploring an operational opportun
Slide 10: H1FY27: Deepening Local Presence Market By Market
H1FY27: Deepening Local Presence Market By Market H1FY27 GEOGRAPHIC REVENUE MIX Rest of World 16.1% UAE 11.8% SAUDI ARABIA AFRICA Saudi Arabia 27.7% +18.5% YoY ~₹470 Mn ₹462.3 mn in Morocco, Kenya & Algeria H1 FY27 combined Algeria 5.8% Morocco 13.1% Kenya 9.4% CORE FTL BUSINESS Turnaround India 16.
Slide 11: Enhancing International Visibility
Enhancing International Visibility Participated in CPHI Milan 2026 engaging with global pharmaceutical industry and exploring potential business opportunities. Investor Presentation - Q2 & H1FY27 10
Slide 12: FABTECH 4.0
FABTECH 4.0 From engineering execution to technology- enabled project delivery Successful More execution Digital Project references Engineering Intelligence THE Higher GROWTH Reference revenue projects FLYWHEEL More projects Integrated Global Procurement Collaboration More references More geographie
Slide 13: Five Structural Drivers
Five Structural Drivers Structural Healthcare Capex Integrated Capability Global Localization Pharma and healthcare manufacturing Process + Air + Water under one Countries are increasingly building capacity is expanding across emerging engineering platform. domestic pharmaceutical manufacturing mark
Slide 14: The Real Moat
The Real Moat Globalization is a Core Growth Engine Five Capabilities → A High-Value Engineering Proposition Global execution Validation capability 62-country experience and growing local presence. Critical for regulated pharmaceutical environments. Engineering know-how Integrated execution Complex
Slide 15: The Core Capabilities
The Core Capabilities Six Core Capability Domains, Developed In-House Every solution is custom-designed and built at our own facilities — covering OSD, sterile liquids, vaccines, oncology, hormones & biosimilars. Cleanroom Process Modular & bio-cleanrooms, HVAC and Powder processing, OSD & tablet co
Slide 16: One Stop Solution for the entire lifecycle
One Stop Solution for the entire lifecycle One platform. Multiple critical systems. One accountable partner. Design Engineering Procurement Construction Management + Project Controls New Plant / Plant Technology Tie-up Project Advisory & Consulting Vendor Selection Upgradation / Transfer Management
Slide 17: Need for Fabtech's Expertise
Need for Fabtech’s Expertise Fabtech is building the critical infrastructure layer for global pharmaceutical manufacturing. Industry Customer Fabtech Competitive Structural Problem Capability Advantage Change Global Order Book Financial Scalable growth Expansion Evidence Inflection Model Investor Pr
Slide 18: Integrated Execution
Integrated Execution Integrated control across the value chain supports delivery discipline, quality and execution visibility. Turnkey Execution (+) Design & Build (+) In-house Manufacturing Greater Execution Control KEY STRATEGIC ADVANTAGES Single-point Control over Faster & more Integrated quality
Slide 19: Solutions for Air
Solutions for Air Comprehensive Clean Air & Containment Solutions Built Containment Clean-air Environment Solutions Equipment + Modular Cleanrooms + Aseptic & Non-Aseptic + LAF Workbench, Vertical Isolators LAF & Mobile LAF Trolleys + Bio-Cleanrooms + Sterility Testing, Filling & + Air & Mist Shower
Slide 20: Solutions for Water
Solutions for Water Comprehensive Water & Utility Solutions + Purified Water Generation & Distribution + Water for Injection (WFI) + Pure Steam Generation & Distribution + Process Vessels Flow Rates Ranging from 500 – 50,000 LPH + CIP & SIP Systems + Chilled Water + Utilities System Investor Present
Slide 21: Solutions for Processes
Solutions for Processes Smart Solutions for Pharma Processes OSD processing Fill & Finish High Shear Mixer Prefilled Syringe Fluid Bed Suite Machine Closed Loop Granulator & Blenders Vial Filling & Capping Machine Coaters, Particle Sizers & Other Ancillaries Investor Presentation - Q2 & H1FY27 20
Slide 22: Business Overview
Business Overview Scaling through in-house arms and strategic partners. (UAE) (INDIA) KSA (KSA) Investor Presentation - Q2 & H1FY27 21
Slide 23: Global Presence
Global Presence Global engineering, local execution 3.9% India UAE Saudi Arabia Jordan 4.8% 11.0% Engineering & Regional HQ & ICV (In Country MENA project 5.4% manufacturing Local team for Value) local team delivery 1.6% sales, service, base for installation 1.5% execution commissioning and KSA JV 2
Slide 24: Turnkey Projects: Delivering Critical Manufacturing Infrastructure
Turnkey Projects: Delivering Critical Manufacturing Infrastructure Selected projects demonstrate Fabtech’s ability to execute complex pharmaceutical manufacturing infrastructure across global markets FIDSON HEALTHCARE HIMALAYA WELLNESS Nigeria UAE 15-month Commissioning Pharmaceutical Manufacturing
Slide 25: Clientele
Clientele Investor Presentation - Q2 & H1FY27 24
Slide 26: Way Forward
Way Forward Investor Presentation - Q2 & H1FY27 25
Slide 27: TAM (Total Addressable Market)
TAM (Total Addressable Market) A large, structurally-funded addressable market Fabtech’s scope covers 60%+ of project spend — Air, Water, Process, Cleanrooms and Utilities. Global TAM Fabtech SAM KSA Build-Out Africa $180B $28–30B $15B+ $60B+ Turnkey pharma & Core geographies: Pharma manufacturing M
Slide 28: The Pharma Self-Reliance Super-Cycle
The Pharma Self-Reliance Super-Cycle Healthcare localization is creating a bigger opportunity Global pharma supply-chain diversification Future adjacency Data Renewable High-spec CGT projects Centres Energy manufacturing in the GCC National manufacturing ambitions New pharma plants Biotech / vaccine
Slide 29: Driving Growth
Driving Growth ALTERNATIVE GREEN SHIELD GLOCALIZATION SOURCING PEB & REVENUE & EARNINGS Key Tax & Local cost EXECUTION CAGR over 3-5 years optimization Procurement Drivers Greater local execution capability optimization Potential ~2-3% margin opportunity Higher project ticket size Improved execution
Slide 30: Annual Highlights
Annual Highlights Investor Presentation - Q2 & H1FY27 29
Slide 31: Key Annual Highlights (1/2)
Key Annual Highlights (1/2) The Company delivered a revenue The closing unexecuted order book Gross receivables stood at Rs 204 Cr CAGR of 28% and an earnings CAGR stood at Rs 900 Cr at the end of FY26, against which advance from of 22% over FY23–FY26. led by order inflow of Rs 500+ Cr customers sto
Slide 32: Key Annual Highlights (2/2)
Key Annual Highlights (2/2) Revenue (INR Mn) Region wise split of Orders (FY26) 0.0% 4107.7 5.4% 3266.7 2261.4 1938 31.7% 2023 2024 2025 2026 43.1% EBITDA (INR Mn) 19.8% 555.6 469.7 383.7 GCC MENA ECO Zone SEA 312.2 ~94% of Order Intake Driven by GCC, MENA & ECO Regions 2023 2024 2025 2026 Investor
Slide 33: Consolidated Income Statement
Consolidated Income Statement Particulars (INR Mn) FY23 FY24 FY25 FY26 Revenue From Operations 1,938.0 2,261.4 3,266.7 4,107.7 Other Income 61.1 44.7 92.7 205.6 29% Total Income 1,999.1 2,306.0 3,359.4 4,313.3 Total Income CAGR Total Expenditure 1,686.9 1,922.3 2,889.8 3,757.7 EBITDA 312.2 383.7 469
Slide 34: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (INR Mn) FY25 FY26 H1FY27 Particulars (INR Mn) FY25 FY26 H1FY27 Equity & Liabilities Assets Equity Property Plant & Equipment 263.4 289.2 274.1 Share Capital 323.9 444.5 444.5 Goodwill 370.0 229.7 241.9 Other Equity 1,407.2 3,753.2 3946.3 Right of use assets 30
Slide 35: Thank You!
Thank You! FABTECH TECHNOLOGIES LTD. (E): cs@fabtechnologies.com www.fabtechnologies.com ® KAPTIFY Consulting Strategy & Investor Relations | Consulting (E): contact@kaptify.in (T): +91-845 288 6099 www.kaptify.in
Fabtech Technologies — Q2 & H1 FY27 Earnings Presentation on 6ix